FORADIL by Novartis is clinical pharmacology mechanism of action formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Approved for asthma, the prevention of bronchospasm only, such and 3 more indications. First approved in 2001.
Drug data last refreshed 5h ago · AI intelligence enriched 6d ago
FORADIL (formoterol fumarate) is a long-acting selective beta-2 adrenergic receptor agonist (LABA) delivered as an inhalation powder for asthma and COPD. It works by stimulating beta-2 receptors in bronchial smooth muscle to induce bronchodilation and inhibit mast cell mediator release. The drug is indicated for prevention of bronchospasm in children 5 years and older with reversible obstructive airways disease, including nocturnal asthma.
Product is approaching end-of-life with declining patent exclusivity; team focus will shift from growth to legacy brand management and cost optimization.
CLINICAL PHARMACOLOGY Mechanism of Action Formoterol fumarate is a long-acting selective beta 2 -adrenergic receptor agonist (beta 2 -agonist). Inhaled formoterol fumarate acts locally in the lung as a bronchodilator. In vitro studies have shown that formoterol has more than 200-fold greater…
Worked on FORADIL at Novartis? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Study of Safety of Foradil in Patients With Persistent Asthma
Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma
A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil® Evaluating Efficacy
Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease
Working on FORADIL offers limited career growth due to LOE approaching status and competitive pressure; roles emphasize cost management, market access strategy, and defending market share rather than innovation or expansion. Positions tied to this product carry higher risk of downsizing or redeployment as generic penetration accelerates post-LOE.